stemmacolore
Search

Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

Impatto del sesso su tossicità ed efficacia delle terapie antitumorali in pazienti trattati per sarcoma presso un Centro di riferimento – SEx Differences In Toxicity and Outcomes in patients treated for Sarcoma in a reference center (SEDITOS)

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
SEDITOS
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio prospettico osservazionale sull’angiosarcoma localizzato di ogni sede: ProStars

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
ProStars
Codice EudraCT
NP
Sponsor/Promotore
Italian Sarcoma group BO
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Valutazione mediante test onco-geriatrico G8 del paziente anziano affetto da patologia neoplastica in fase avanzata candidato a ricevere un trattamento innovativo

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
ONC-OLD
Codice EudraCT
NP
Sponsor/Promotore
Università degli Studi di Bologna
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Studio randomizzato, controllato, in aperto di fase IIb/III su lurbinectedin in combinazione con doxorubicina rispetto a doxorubicina in monoterapia come trattamento di prima linea in pazienti con leiomiosarcoma metastatico

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
PM1183-C-010-22 (SaLuDo)
Codice EudraCT
2022-502975-45-00
Sponsor/Promotore
Pharma Mar S.A.
Tipologia
Sperimentale
Fase
II / III
Unità Operativa
Principal Investigator

Studio internazionale di fase 3, randomizzato, multicentrico, in aperto su ripretinib rispetto a sunitinib in pazienti con tumore stromale gastrointestinale (GIST) in stadio avanzato con mutazioni del gene KIT sull’esone 11 e mutazioni concomitanti del gene KIT sull’esone 17 e/o sull’esone 18, precedentemente trattati con imatinib (INSIGHT)

Stato
Aperto - reclutamento in corso
Codice studio
DCC-2618-03-003
Codice EudraCT
2022-503058-37-00
Sponsor/Promotore
Deciphera pharmaceuticals llc
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator

Brightline-1: Studio multicentrico randomizzato, in aperto di fase II/III, volto a confrontare BI 907828 e doxorubicina come trattamento di prima linea in pazienti con liposarcoma dedifferenziato avanzato.

Patologie
Stato
Attivo - reclutamento chiuso
Codice studio
1403-0008 (Brightline-1)
Codice EudraCT
2021-002392-20
Sponsor/Promotore
Boehringer Ingelheim
Tipologia
Sperimentale
Fase
II / III
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top